香港浸會大學基金2022-2023年報

19 University’s Recent Developments 大學最新發展 HKBU’s Centre for Chinese Herbal Medicine Drug Development has focused on innovative Chinese medicine research for treating gastrointestinal and immune-related diseases. The team led by Professor Bian Zhaoxiang, MH, HKBU’s Associate Vice-President (Chinese Medicine Development), has developed novel Chinese medicine treatment for constipation. This is the first new botanical drug developed in Hong Kong to be authorised by the U.S. Food and Drug Administration to conduct a clinical trial in the United States. 浸大轄下中藥創新研發中心一直針對腸道及免疫性疾病進  行研究。浸大協理副校長（中醫藥發展）卞兆祥教授， MH 的團隊研發出能治療慢性便秘的創新中藥，更是首次有由  香港研發、以中草藥為本的新藥獲美國食品及藥物管理局批 准進行臨床研究。 Global warming attracts intense attention worldwide. A research team led by Professor Gao Meng of HKBU’s Department of Geography has developed a statistical model that uses patterns of springtime warming in the western Pacific Ocean, western Indian Ocean and Ross Sea to predict the frequency of summertime co-occurrence of heat wave and air pollution in China. The model provides useful information for government authorities taking advance action to mitigate damage from these hazards. 近期全球暖化問題再次引起廣泛關注。浸大地理系高蒙教授 領導的團隊利用西太平洋、西印度洋和羅斯海春季暖化的模 式建構統計模型，預測中國在夏季同時出現熱浪和空氣污染 的頻率，可為政府提供有用資訊，從而及早採取行動，以減 輕上述災害造成的破壞。 A team led by Professor Li Min, Associate Dean of Chinese Medicine, has developed a novel drug delivery system for Alzhemier’s disease (AD). The researchers have engineered exosomes, to effectively carry the bioactive compound extracted from the Chinese herbal medicine Gouteng to the brain of mice with AD which provides hope that a cure for AD may be possible in the future. 浸大中醫藥學院副院長李敏教授領導的研究團隊開發一種創 新的藥物傳送方式，能有效將從中草藥鈎藤提取的生物活性 化合物，攜帶到患有阿茲海默症小鼠的大腦中，為未來發展 出治療阿茲海默症的藥物帶來希望。 Dr. Allen Cheung, Assistant Professor of HKBU’s Department of Biology, and other researchers have found that urine tests for human cytomegalovirus (HCMV) can identify the risk of end-organ diseases such as pneumonitis, gastrointestinal ulcers, hepatitis and myocarditis earlier in patients infected with human immunodeficiency virus type 1 (HIV-1). Anti-HCMV treatments could halve the incidence of lung and cardiovascular end-organ diseases. 浸大生物系助理教授張嘉龍博士及與其他研究人員發現，  檢測尿液中的人類巨細胞病毒，能提早識別人類免疫力缺乏  病毒一型（ HIV-1 ）感染者罹患非感染性肺炎、腸胃潰瘍、  肝炎和心肌炎等疾病的風險，而相應治療能把肺部及心血管 的終端器官疾病發病率降低一半。 Innovative Research 創新研究